Form 4: Ionis Pharmaceuticals CEO Brett Monia Reports Stock Transactions

Ionis Pharmaceuticals CEO Brett Monia reports the acquisition and disposal of company stock following the vesting of performance-based restricted stock units.

Summary

• Brett P. Monia, CEO of Ionis Pharmaceuticals, reported transactions involving the company's common stock.
• On January 30, 2025, Monia acquired 25,372 shares upon the vesting of performance-based restricted stock units (PRSUs) at a price of $0.00.
• These PRSUs vested based on the company's relative total shareholder return compared to a peer group, achieving 150% of the target shares.
• On January 31, 2025, Monia sold 13,242 shares at a weighted average price of $32.4464, with individual sales ranging from $32.04 to $32.81.
• Following these transactions, Monia directly owns 219,526 shares of Ionis Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of PRSUs suggests the company met performance goals. The CEO's sale of shares is a normal activity and doesn't necessarily indicate a negative outlook.

Positives

• The vesting of PRSUs indicates that Ionis Pharmaceuticals achieved a pre-established performance goal related to total shareholder return.
• The performance goal achievement resulted in a vest of 150% of target shares, suggesting strong performance relative to its peer group.

Industry Context

Executive stock transactions are common and closely watched as they can provide insights into management's perspective on the company's valuation and future prospects. The vesting of PRSUs indicates the achievement of performance goals, which is generally viewed positively.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PRSUs to align management's interests with those of shareholders.
• The specific performance metrics and vesting schedules vary across companies and industries, but relative total shareholder return is a common metric.
• Comparing Ionis Pharmaceuticals' performance against its peer group is a standard practice in assessing executive compensation and company performance.
• Companies like Alnylam Pharmaceuticals and Biogen also use similar performance-based compensation strategies.

Stakeholder Impact

• The vesting of PRSUs and subsequent stock sale may have a minor impact on shareholders, potentially influencing the stock price in the short term.
• The achievement of performance goals underlying the PRSU vesting is generally positive for shareholders.

Key Dates